These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30137686)

  • 21. Efficacy and Safety of Biweekly Docetaxel in Combination with Nedaplatin as Second-line Chemotherapy for Unresectable or Recurrent Esophageal Cancer.
    Kanekiyo S; Takeda S; Nakajima M; Nishiyama M; Kitahara M; Shindou Y; Michihisa I; Abe T; Yoshino S; Hazama S; Nagano H
    Anticancer Res; 2016 Apr; 36(4):1923-7. PubMed ID: 27069181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy].
    Kimura Y; Shiraishi O; Kawakami H; Ueda H; Okuno T; Hiraki Y; Kato H; Iwama M; Yasuda A; Shinkai M; Chikugo T; Imano M; Imamoto H; Nakagawa K; Yasuda T
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):1812-1814. PubMed ID: 30692362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
    Ohnuma H; Sato Y; Hirakawa M; Okagawa Y; Osuga T; Hayashi T; Sato T; Miyanishi K; Kobune M; Takimoto R; Sagawa T; Hori M; Someya M; Nakata K; Sakata K; Takayama T; Kato J
    Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):382-90. PubMed ID: 26232855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T; Yamanaka T; Seto T; Daga H; Goto K; Saka H; Sugawara S; Takahashi T; Yokota S; Kaneda H; Kawaguchi T; Nagase S; Oguri T; Iwamoto Y; Nishimura T; Hattori Y; Nakagawa K; Nakanishi Y; Yamamoto N;
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
    J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Open-Label Single-Arm Phase II Study of Treatment with Neoadjuvant S-1 Plus Cisplatin for Clinical Stage III Squamous Cell Carcinoma of the Esophagus.
    Kanda M; Koike M; Iwata N; Shimizu D; Tanaka C; Hattori N; Hayashi M; Yamada S; Omae K; Nakayama G; Kodera Y
    Oncologist; 2020 Nov; 25(11):e1650-e1654. PubMed ID: 32557987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
    Miyazaki A; Kobayashi J; Yamamoto T; Kido Y; Takemura K; Abe M; Tomihara K; Dehari H; Nakamori K; Nagai I; Hiratsuka H
    Oral Oncol; 2008 May; 44(5):471-6. PubMed ID: 17826308
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
    Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
    Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
    Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
    Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
    Li X; Lin W; Wang H; Lin W; Lin S; Lin Y
    Med Oncol; 2013 Dec; 30(4):746. PubMed ID: 24122256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
    Hironaka S; Tsubosa Y; Mizusawa J; Kii T; Kato K; Tsushima T; Chin K; Tomori A; Okuno T; Taniki T; Ura T; Matsushita H; Kojima T; Doki Y; Kusaba H; Fujitani K; Taira K; Seki S; Nakamura T; Kitagawa Y;
    Cancer Sci; 2014 Sep; 105(9):1189-95. PubMed ID: 25041052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-institute phase I/II trial of alternating chemoradiotherapy with 5-FU and nedaplatin for esophageal carcinoma.
    Kodaira T; Fuwa N; Kamata M; Furutani K; Tachibana H; Yamazaki T
    Anticancer Res; 2006; 26(1B):471-8. PubMed ID: 16739307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
    Osaka Y; Takagi Y; Hoshino S; Tachibana S; Tsuchida A; Aoki T
    Dis Esophagus; 2006; 19(6):473-6. PubMed ID: 17069591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial.
    Shiraishi O; Makino T; Yamasaki M; Tanaka K; Yamashita K; Ishida T; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Doki Y; Yasuda T
    Esophagus; 2021 Oct; 18(4):825-834. PubMed ID: 33738656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.